Maintenance of treatment response in chronic plaque psoriasis patients continuing treatment or discontinuing treatment with tildrakizumab in a 64-week, randomized controlled, phase 3 trial

Conference Proceedings

K Papp, AB Kimball, S Tyring, R Sinclair, Anish Metha, N Cichanowitz, Q Li, S Green, Carmen La Rosa

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | MOSBY-ELSEVIER | Published : 2017

This study was funded by Merck & Co., Inc.